BPMC Blueprint Medicines Corporation

78.48
+3.92  (+5%)
Previous Close 74.56
Open 74.84
Price To Book 7.48
Market Cap 3,861,382,535
Shares 49,202,122
Volume 435,480
Short Ratio
Av. Daily Volume 453,212
Stock charts supplied by TradingView

NewsSee all news

  1. Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced

  2. Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  3. Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its

  4. Blueprint Medicines to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 initial data due at ASH December 8, 2019 at 6pm ET.
Avapritinib BLU-285 - PIONEER
Indolent and smoldering systemic mastocytosis (SM)
PDUFA date under priority review February 14, 2020. Likely to be extended due to requested data from Voyager trial (2Q 2020).
Avapritinib BLU-285
PDGFRα driven Gastrointestinal stromal tumors (GIST) - 4th line
Phase 1 China enrolment to commence mid-2019.
BLU-554
Advanced hepatocellular carcinoma (HCC)
Phase 1 updated data at ASCO 2019 - 60% ORR in post-platinum RET-fusion NSCLC and 63% ORR in RET-mutant MTC patients. NDA filing due 1Q 2020.
BLU-667 - ARROW
RET-altered solid tumors
Phase 2 enrolment to be completed 2H 2019. NDA filing due 1Q 2020.
Avapritinib BLU-285 - PATHFINDER
Advanced Systemic mastocytosis (SM)
NDA filing due 1Q 2020.
Avapritinib BLU-285 - EXPLORER
Advanced Systemic mastocytosis (SM)
Phase 3 data due 2Q 2020.
Avapritinib - Voyager
Gastrointestinal stromal tumors (GIST)
Phase 2 trial to be initiated 4Q 2019.
BLU-782
Fibrodysplasia ossificans progressiva (FOP)
Phase 3 trial to be initiated 4Q 2019.
Pralsetinib (BLU-667)
First-line RET-fusion non-small cell lung cancer (NSCLC)
Phase 2 trial to be initiated 2H 2019.
Pralsetinib (BLU-667) and osimertinib
EGFR-mutant non-small cell lung cancer (NSCLC)

Latest News

  1. Blueprint Medicines to Present at Jefferies 2019 London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 14, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced

  2. Blueprint Medicines to Present Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis at 61st ASH Annual Meeting and Exposition

    CAMBRIDGE, Mass., Nov. 6, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced

  3. Blueprint Medicines Outlines Precision Therapy Research Vision, Provides Update on Discovery and Clinical-Stage Portfolio at R&D Day and Reports Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 5, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, is hosting its

  4. Blueprint Medicines to Present at Upcoming Investor Conferences in September

    CAMBRIDGE, Mass., Aug. 28, 2019 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy,  today announced